Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Allison Berger"'
Autor:
Sean A. Beausoleil, Michael Milhollen, Stephen J. Blakemore, Anthony Possemato, Claudia M. Espitia, Pete Smith, Michael P. Thomas, Allison Berger, Steffan T. Nawrocki, Kevin R. Kelly, Jennifer S. Carew
Publikováno v:
Clinical Cancer Research. 19:3577-3590
Purpose: Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of treatment failure and novel therapeutic strategies are urgently needed. MLN4924 is a NEDDylation inhibitor currently u
Autor:
Yiguo Hu, Samir B. Amin, Dharminder Chauhan, Yu-Tzu Tai, Ze Tian, Allison Berger, Paul G. Richardson, Kenneth C. Anderson, Jianjun Zhao
Publikováno v:
Blood. 120:3958-3967
miRs play a critical role in tumor pathogenesis as either oncogenes or tumor-suppressor genes. However, the role of miRs and their regulation in response to proteasome inhibitors in multiple myeloma (MM) is unclear. In the current study, miR profilin
Autor:
Bret Bannerman, Larry Dick, Mark Rolfe, Li Yu, Paul Hales, Jie Yu, Frank J. Bruzzese, Mark Manfredi, Edmund Lee, Michael Fitzgerald, Yueying Cao, Khristofer Garcia, Jane Liu, Joe Bolen, Erik Kupperman, Jonathan L. Blank, Paul E. Fleming, Yu Yang, Christopher Tsu, Allison Berger
Publikováno v:
Cancer Research. 70:1970-1980
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, severalgroups are pursuing the development
Autor:
Jill Donelan, Stephen Tirrell, Erik Koenig, Bradley Stringer, Kristen Jordan, Cindy Q. Xia, Mark Manfredi, Allison Berger, Yu Yang, Angel Maldonado Lopez, James Garnsey, Nelson Rhodes, Katherine Galvin, Ben Amidon, Paul Hales, Nibedita Chattopadhyay, Hugues Bernard, Bret Bannerman, Greg Hather
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
PLoS ONE
PLoS ONE
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to
Autor:
Olga Tayber, Erik Kupperman, Zhi Li, Joseph B. Bolen, Ping Li, Kristen Bano, Jennifer Terkelsen, Allison Berger, Brian G Van Ness, Michael D. Pickard, Matthew D. Silva, Mary Carsillo, Paul Hales, Michael Fitzgerald, Siegfried Janz, Ozlem Subakan, Daniel P. Bradley, Mark Manfredi, Edmund Lee, Vishala T. Neppalli, Bret Bannerman, Jill Donelan, Raymond W. Liu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort
Autor:
Mark Manfredi, Erik Kupperman, Ling Xu, Paul E. Fleming, Johan Monbaliu, Christopher F. Claiborne, Lawrence Dick, Matthew Jones, Paul Hales, Bret Bannerman, Joseph B. Bolen, Jie Yu, Christopher Tsu, Allison Berger
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To investigate whether clinically relevant levels of epigallocatechin gallate (EGCG, a component of green tea) or vitamin C (ascorbic acid) could antagonize bortezomib antitumor activity in CWR22 human prostate xenograft tumors. Methods The p